NVS - Novartis AG
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 96.25 |
| Open | 97.01 |
| Bid | 96.90 x 800 |
| Ask | 96.92 x 800 |
| Day's Range | 96.56 - 97.16 |
| 52 Week Range | 74.09 - 105.56 |
| Volume | |
| Avg. Volume | 2,167,347 |
| Market Cap | 205.39B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 29.72 |
| EPS (TTM) | 3.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.50 (3.62%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | 110.75 |
Fair Value
Related Research
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
GlobeNewswireSandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent company Basel, as a global life sciences center, ideally located to attract top talent Basel, June 1, 2023 — Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel. The Sandoz AG headquarters plans to move to a lan
ZacksBristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
ZacksSanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
ZacksKodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
ZacksAre Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
ZacksNovo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
ZacksBristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
ZacksTime to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
ZacksAlimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
- GlobeNewswire
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-
ZacksNovo Nordisk (NVO) Collaborates for Gene-Editing Therapies
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
ZacksZacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
ZacksNovo Nordisk (NVO) Announces Positive Obesity Program Data
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
ZacksInvest in These Dividend Growth Stocks Amid Default Fears
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
ZacksAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
ZacksNovartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Barrons.comNovartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
Medicare’s new ability to negotiate some drug prices is a "super high concern," according to CEO Vas Narasimhan.
ZacksWhy Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Simply Wall St.Is Novartis AG's (VTX:NOVN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...
Insider Monkey20 Richest Countries in Europe
In this article, we discuss the 20 richest countries in Europe. If you want to see the top 5 richest countries in the region, check out 5 Richest Countries in Europe. As per the European Commission, the European economy is showing resilience despite global challenges. The first quarter of 2023 saw moderate growth due to […]
ZacksRoche's (RHHBY) MS Drug Meets Goals in the Phase II Study
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.